Zymeworks Inc (ZYME)

Zymeworks News & Analysis

• 

  Zymeworks and BeiGene Terminate zanidatamab zovodotin Deal,

  On September 18, 2023, Zymeworks (NASDAQ:ZYME), a subsidiary of Zymeworks Inc . (the “Company”), and BeiGene , Ltd. (NASDAQ:BGNE) entered into a Termination Agreement (the “Termination...

• 

  Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca, Taiho Oncology, Basilea, Eisai, Zymeworks, BeiGene, Xencor, BMS, Leap

  New York, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca,...

• 

  Zymeworks Appoints Carlos E. Campoy to its Board

  Zymeworks Inc . (Nasdaq: NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to...

• 

  Zymeworks Set to Join Russell 3000, Russell 2000, and Russell Microcap Indexes

  Zymeworks Inc . (Nasdaq: NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell...

• 

  Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data

  Jazz Pharmaceuticals plc (Nasdaq: NASDAQ:JAZZ) and Zymeworks Inc . (Nasdaq: NASDAQ:ZYME) today presented positive pivotal trial data, including new data on progression-free survival...

• 

  Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer

  Zymeworks Inc . (Nasdaq: NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the departure of Neil Klompas, President...

• 

  Citi maintains Zymeworks at 'buy' with a price target of $18.00

  An analyst from Citi maintained Zymeworks (NASDAQ: ZYME) at 'buy' with a price target of $18.00 from a prior price target of $17.00. Prior to this rating, Zymeworks had 8 buy ratings, 3...

• 

  Stifel maintains Zymeworks at 'buy' with a price target of $19.00

  An analyst from Stifel maintained Zymeworks (NASDAQ: ZYME) at 'buy' and a price target of $19.00 from a prior price target of $18.00. Prior to this rating, Zymeworks had 8 buy ratings, 3...

• 

  Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs

  Zymeworks Inc . (Nasdaq: NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced 11 presentations including new data from...

• 

  Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

  Zymeworks Inc . (Nasdaq: NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its...

• 

  JPMorgan maintains Zymeworks at Neutral

  A JPMorgan analyst maintained Zymeworks (NASDAQ: ZYME) at Neutral and a price target of $9.00 from a prior price target of $8.00. Prior to this rating, Zymeworks had 8 buy ratings, 3 hold...

• 

  Zymeworks Misses Q4 EPS, Revenue Beats

  Zymeworks (NASDAQ:ZYME) reported Q4 EPS of $4.71, $0.13 worse than the analyst estimate of $4.84. Revenue for the quarter came in at $402.49 million versus the consensus estimate of $371.3...

• 

  Zymeworks earnings missed by $0.13, revenue topped estimates

  Investing.com - Zymeworks (NASDAQ: ZYME) reported first quarter EPS of $4.71, $0.13 worse than the analyst estimate of $4.84. Revenue for the quarter came in at $402.49M versus the consensus...

• 

  Zymeworks Earnings beat, Revenue misses In Q3

  Investing.com - Zymeworks reported on Tuesday third quarter {{erl-1008763||earnings that beat analysts' forecasts and revenue that fell short of expectations. Zymeworks announced earnings...

• 

  Zymeworks Tops Q3 EPS by 23c

  Zymeworks (ZYME) reported Q3 EPS of ($0.66), $0.23 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $5.55...

• 

  Zymeworks Misses Q2 EPS by 2c

  Zymeworks (NYSE:ZYME) reported Q2 EPS of ($0.97), $0.02 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $5.44 million versus the consensus estimate of $7.09...

• 

  Zymeworks Gains as Would-Be Suitor All Blue Capital Names Medical Advisors, Sends Letter Demanding Takeover Talks

  Zymeworks (NYSE:ZYME) shares jumped 11% intra-day after All Blue Capital named Siddhartha Mukherjee, MD as a medical advisor in support of its proposed $10.50 per share acquisition offer for...

• 

  Zymeworks Tops Q1 EPS by 48c

  Zymeworks (NYSE:ZYME) reported Q1 EPS of ($1.19), $0.48 better than the analyst estimate of ($1.67). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $3.47...

• 

  Pre-Open Stock Movers 04/29: Zymeworks Gain on Takeover Chatter; Amazon, Robinhood, Intel Fall Post Earnings (more...)

  Pre-Open Stock Movers: Finch Therapeutics Group (NASDAQ:FNCH), Inc. (Nasdaq: FNCH) 70% HIGHER; announced that the FDA has removed the clinical hold on Finchs investigational new drug...

• 

  After-Hours Stock Movers 04/28: Zymeworks Gains on Takeover Talk; Amazon Sinks on Miss, Apple Lower on Supply Chain Warning (more...)

  After-Hours Stock Movers:Zymeworks (NYSE:ZYME) 36% HIGHER; approached by All Blue Capital about a takeover at $10.50 per share, Reuters reportedAccolade (ACCD) 31% LOWER; reported Q4 EPS of...